Chemical Diversity Labs Inc., of San Diego, appointed Stanley Lang vice president of chemistry.
Connetics Corp., of Palo Alto, Calif., appointed Joseph Finster senior vice president, marketing.
Deltagen Inc., of Redwood City, Calif., appointed Stephen Peroutka vice president of clinical research.
Demegen Inc., of Pittsburgh, promoted David Rothstein to director of research and Philip Friden was added to its scientific advisory board.
DoubleTwist Inc., of Oakland, Calif., appointed Simon Tomlinson vice president of worldwide sales and Gregory Thayer chief financial officer and general counsel.
Entropin Inc., of Indio, Calif., appointed Dennis Metzler to its board.
Epoch Biosciences Inc., of Bothell, Wash., appointed Walt Mahoney senior vice president, research and development.
Exelixis Inc., of South San Francisco, added Robert Myers as executive vice president, pharmaceuticals.
Genentech Inc., of South San Francisco, appointed Mark Ahn vice president, hematology sales and marketing.
Genmab A/S, of Copenhagen, Denmark, appointed Ernst Schweizer head of business development.
Graffinity Pharmaceutical Design GmbH, of Heidelberg, Germany, appointed Victor Matassa vice president, research and development.
Icogen Corp., of Seattle, added James Glavin and Gregory Sessler to its board.
ILEX Oncology Inc., of San Antonio, added Timothy Ruane as senior vice president, business management; named Michael Dwyer executive vice president, chief financial officer; and appointed Gregory Weaver vice president, strategic development.
Institute of Forest Biotechnology, of Research Triangle Park, N.C., named Edward Makowski executive director.
InterMune Inc., of Brisbane, Calif., promoted David Cory to senior vice president of sales and marketing.
Introgen Therapeutics Inc., of Austin, Texas, said its president and CEO, David Nance, was appointed to the Governor’s Council on Science and Biotechnology Development. Introgen also appointed Janet Gregory senior director of clinical development, Keith Coffee director of clinical sciences and Bruce Ross director of clinical operations.
Kosan Biosciences Inc., of Hayward, Calif., promoted Michael Ostrach to president and chief operating officer; Robert Johnson to senior vice president, medical affairs and corporate development; Susan Kanaya to senior vice president, finance and chief financial officer; and Kevin Kaster to senior vice president, legal affairs.
L.E.K. Consulting LLC, of Boston, added Ken Noonan as partner to its London office.
La Jolla Pharmaceutical Co., of San Diego, appointed Bruce Bennett vice president of manufacturing.
LifeSpan Biosciences Inc., of Seattle, appointed Daniel Chen as vice president, marketing and business development.
MDS Proteomics, a division of MDS Inc., of Toronto, added Gregg Morin and Mark Scheideler as vice presidents of drug discovery.
Medarex Inc., of Princeton, N.J., added Wen Ryan as vice president of biopharmaceutical development.
Memory Pharmaceuticals Corp., of Montvale, N.J., appointed Gardiner Smith vice president, business development.
Morphotek Inc., of Philadelphia, appointed David King to its board and William Heilman vice president of business development.
Neurogen Corp., of Branford, Conn., elected Craig Saxton to its board.
NitroMed Inc., of Bedford, Mass., appointed James Cappola senior vice president of clinical and regulatory affairs.
Onyvax Ltd., of London, appointed David Holbrook business development director.
Organogenesis Inc., of Canton, Mass., promoted Steven Bernitz to executive vice president and chief operating officer.
PDI Inc., of Upper Saddle River, N.J., appointed John Federspiel to its board.
Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., promoted Thomas Boyd to vice president, preclinical development and project management, and Philip Yachmetz to vice president and general counsel.